Holen Sie sich die Stockscreener-App
10.40
0.87%
0.09
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
HC Wainwright Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) - MarketBeat
Vir Biotechnology appoints new Chief Technical Officer By Investing.com - Investing.com Canada
Vir Biotechnology Inc. (VIR) Stock Overview and Recent Developments – Market - HPBL
Vir Biotechnology Shares Surge After Opening Higher: A Market Overview – Market - HPBL
Vir Biotechnology, Inc. Announces Executive Changes -January 30, 2025 at 07:51 am EST - Marketscreener.com
Vir Biotechnology appoints new Chief Technical Officer - Investing.com
Vir Biotechnology Inc. (VIR) Announces CTO Departure - StreetInsider.com
Trading (VIR) With Integrated Risk Controls - Stock Traders Daily
Vir Biotechnology Phase 1 Data on Dual-Masked T-Cell Engagers (TCEs) – Market - HPBL
Vir Biotechnology (NASDAQ:VIR) Shares Down 3.8%Should You Sell? - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Shares Up 6.3%What's Next? - MarketBeat
Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now - Insider Monkey
Hepatitis B Virus Infection Clinical and Non-Clinical Studies, - openPR
Vir, Sana gain new modality POC: BioCentury’s Clinical Report - BioCentury
JP Morgan Week 2025 – Marianne De Backer - pharmaphorum
What is Leerink Partnrs’ Forecast for VIR Q1 Earnings? - Defense World
Analysts Set Vir Biotechnology, Inc. (NASDAQ:VIR) PT at $34.83 - Defense World
Vir Biotechnology (NASDAQ:VIR) Shares Down 10.4%Here's What Happened - MarketBeat
Q1 Earnings Estimate for VIR Issued By Leerink Partnrs - MarketBeat
JPMorgan Chase & Co. Has $8.14 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Q2 Earnings Estimate for VIR Issued By Leerink Partnrs - MarketBeat
Analysts Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $34.83 - MarketBeat
Leerink Partners Boosts Vir Biotechnology (NASDAQ:VIR) Price Target to $20.00 - MarketBeat
Nordea Investment Management AB Sells 286,600 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) - MarketBeat
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 - MSN
Vir Biotech upgraded at Morgan Stanley on cancer drug data - MSN
Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment - MSN
Morgan Stanley Doubles Vir Biotechnology Price ForecastHere's Why - AOL
Vir Biotechnology (NASDAQ:VIR) Earns "Buy" Rating from HC Wainwright - MarketBeat
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates - MSN
Morgan Stanley Upgrades Vir Biotechnology (VIR) - MSN
Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58% - GuruFocus.com
Insider Sell: Vicki Sato Sells Shares of Vir Biotechnology Inc (VIR) - GuruFocus.com
Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong? (NASDAQ:VIR) - Seeking Alpha
Vir Biotechnology (NASDAQ:VIR) Upgraded by Morgan Stanley to "Overweight" Rating - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Given New $14.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 By Investing.com - Investing.com Canada
Vir Biotechnology Reports Promising Trial Results for Cancer Therapies - Yahoo Finance
Morgan Stanley Sees 67% Upside Potential for Vir Biotechnology S - GuruFocus.com
Morgan Stanley Sees 67% Upside Potential for Vir Biotechnology Stock - Yahoo Finance
Vir Biotechnology stock soars 58%: Is it still a buy? - Dataconomy
Vir Biotechnology (NASDAQ:VIR) Sets New 52-Week HighHere's Why - MarketBeat
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):